Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Dél-Korea2. fázis

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
Seoul National University Hospital
Hol
Guri-si és Seoul (Dél-Korea)Mind a 3 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
29 fő, tervezett
Kezdés
2023. júl. 7.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Bortezomib
A regiszteradat frissítve
2026. február 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with immune thrombocytopenia (ITP, a low platelet count caused by the immune system) that came back or did not respond to earlier treatments. They will receive bortezomib.

Életkor
19 years and older
Nem
Men and women
A betegség stádiuma
Primary or secondary immune thrombocytopenia that relapsed or did not respond to treatment. Platelets must be below 30 x 109/L and treatment must be needed.
Korábbi kezelés
Relapsed or no response after corticosteroids (prednisolone cumulative dose 5.6mg/kg or more, or dexamethasone cumulative dose 80mg or more), unless corticosteroids cannot be used. Also relapsed or no response after at least 2 other kinds of treatment, such as splenectomy, eltrombopag or romiplostim, rituximab, azathioprine, cyclosporine or MMF, vincristine or cyclophosphamide, danazol, dapsone or alemtuzumab.
Biomarker vagy leletérték
A bone marrow test within the past 5 years must show the low platelets are not caused by the bone marrow. Also at least one of these: a full platelet response (plt >100k) to immunoglobulin therapy, proven anti-platelet antibody, or proven autoimmune markers (such as Helicobacter IgG, ANA, ACA, NSI). Women who can become pregnant need a negative pregnancy test within 28 days before starting.

A részvétel fő kizáró okai

  • Pregnant or breastfeeding women
  • Allergy to bortezomib, or Grade 2 or higher nerve damage (peripheral neuropathy) needing drugs
  • Severe or uncontrolled active infection, or HBV, HCV or HIV unless stable on antiviral treatment
  • Currently having chemotherapy or in another clinical trial
  • Poor organ function: total bilirubin > 3 x ULN, creatinine > 1.5 x ULN, or AST & ALT > 3 x ULN

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Men and women 19 years of age and older
  • Patients diagnosed with immune thrombocytopenia (primary or secondary)
  • (Patients with at least one of B, C, or D meeting A below.) A.A person who has been confirmed not to be due to a cause of decreased platelet production in the bone marrow in the results of bone marrow examination within the past 5 years. (Bone marrow examination is required if there is no bone marrow examination result within the last 5 years.) B.After being diagnosed with ITP, there has been a case of complete platelet response with plt >100k in immunoglobulin therapy; C.Patients suspected of having primary immune thrombocytopenia with proven anti-platelet antibody., D.Helicobacter IgG, antinuclear antibody (ANA), anticardiolipin antibody (ACA), nonspecific inhibitor (NSI), etc. have been proven, and secondary immune thrombocytopenia caused by autoimmune disease is suspected
  • platelets <30 x 109/L
  • Patients in need of clinical treatment
  • Patients who have relapsed or refractory after receiving treatment with corticosteroids (prednisolone cumulative dose 5.6mg/kg (0.8mg/kg 1 week) or more or dexamethasone cumulative dose 80mg (20mg 4 days) or more)., However, there are exceptions when corticosteroids are contraindicated
  • Patients who have been relapsed or refractory after receiving at least 2 treatments with a mechanism other than corticosteroids
  • Patients who underwent two different treatments from among the treatment methods below; Splenectomy; eltrombopag or romiplostim; Rituximab treatment; Azathioprine; cyclosporine or mycophenolate mofetil(MMF); vincristine or cyclophosphamide; danazol; dapsone; Alemtuzumab
  • Female patients of childbearing potential should have a negative urine or serum pregnancy test within 28 days before starting administration of the test drug
  • Patients who voluntarily or legal guardians have given written consent to participate in this clinical trial

Ki nem vehet részt

  • Patients with Grade 2 or higher peripheral neuropathy requiring drug treatment
  • Patients currently undergoing chemotherapy
  • Patients allergic to bortezomib
  • Patients with severe or uncontrolled active infection
  • HBV, HCV carrier or HIV patient. (However, if the patient is being stably maintained with antiviral treatment, and the expert opinion determines that it is possible to participate in the clinical trial along with antiviral treatment and prevention, participation is possible.)
  • Patients whose bone marrow did not recover after cancer treatment, or whose cause other than immune destruction was confirmed by bone marrow examination, such as thrombocytopenia due to intramedullary abnormalities. However, if the presence of anti-platelet antibodies is proven and thrombocytopenia due to immune destruction is strongly suspected clinically, registration is possible even if there are other causes of thrombocytopenia.)
  • Patients with inadequate organ function; total bilirubin > 3 x ULN; creatinine > 1.5 x ULN; liver function test AST(SGOT) \& ALT(SGPT) > 3 x ULN
  • Patients who may become pregnant. However, women of childbearing age(If postmenopausal women are not of childbearing age, they must have been menstruating for at least 12 months.) who have not undergone sterilization can participate in the clinical trial only if the pregnancy test is negative. And, effective contraception must be maintained throughout the entire trial period
  • pregnant, lactating women
  • Patients with significant immunoglobulin degradation in the immunoglobulin profile
  • Patients currently participating in other clinical trials
  • Patients who are not considered suitable for participation in clinical trials in the opinion of the researcher

Ez a vizsgálat jelenleg itt érhető el: Dél-Korea.

  • Seoul National University Bundang HospitalGuri-si, Dél-KoreaContact: Ji Yoon LeeRésztvevőt keres
  • Seoul National University HospitalSeoul, Dél-KoreaContact: Dong-Yeop Shin, M.D.Résztvevőt keres
  • SMG-SNU Boramae Medical CenterSeoul, Dél-KoreaContact: Songyi ParkRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia

A vizsgálat csoportja

  • TreatmentA vizsgált kezelés

    Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.

    Kezelés: Bortezomib

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2 Study to Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. február 2.